Multiple Sclerosis | Disease Landscape & Forecast | G7 | 2024
The market for multiple sclerosis (MS) disease-modifying therapies (DMTs) continues to fragment as newer entrants in established classes such as TG Therapeutics’ Briumvi, Novartis’s Kesimpta, and Bristol Myers Squibb’s Zeposia propel ongoing shifts and intensify competition in the saturated relapsing MS market. Meanwhile, many developers have renewed focus on developing treatments for the underserved progressive MS population, including Sanofi and Roche’s BTK inhibitors and several other novel products. In addition, the U.S. launch of generics competition for Tecfidera, Gilenya, and Aubagio and the impending entry of generic orals in Europe will constrain the uptake of follow-on compounds and exert new pressure on the overall market as reimbursement authorities struggle to rein in healthcare costs. Understanding these market forces will be key to the success of current and future players in this evolving market.
Questions answered:
- What is the commercial outlook for emerging oral BTK inhibitors in relapsing and progressive forms of MS?
- How have newer S1P receptor modulators and novel fumarates influenced competition between classes, and how will this competition evolve over the next 10 years?
- How will Briumvi and Kesimpta impact the use of Ocrevus in the relapsing and progressive MS markets?
- How will the recent and anticipated launch of oral generics’ competition impact the MS market?
- What do key opinion leaders think about emerging agents for progressive MS, and what is the commercial outlook for these therapies?
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: 31 country-specific interviews with thought-leading neurologists, supported by survey data collected for this content and other Clarivate research.
Epidemiology: Diagnosed prevalence of MS by country, segmented by CIS, RR-MS, SP-MS, and PP-MS; drug-treated cases.
Drug treatments: Coverage of key current and emerging therapies.
Key companies: AB Science, Banner Life Sciences, Biogen, Bristol Myers Squibb, Immunic Therapeutics, InnoCare Pharma Limited, Johnson & Johnson Innovative Medicine, Kyverna Therapeutics, Merck KGaA / EMD Serono, Mylan, Mapi Pharma, Novartis, Roche / Genentech, Sanofi, Teva, TG Therapeutics.
Market forecast features: Patient-based market forecast extending through 2033, segmented by brands and generics / biosimilars.
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research.
Key features
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
